Catalyst Event
Yuhan Corp (000100) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
5/29/2026, 12:00:00 AM
Updated clinical data for 'Leclaza' (lazertinib) from the CHRYSALIS-2 study is scheduled to be presented at the ASCO 2026 conference starting May 29, 2026; medium importance estimated due to potential impact on global market expansion, scheduled.
Korean Translation
2026년 5월 29일 시작되는 ASCO 2026에서 '렉라자'의 CHRYSALIS-2 임상 데이터 발표 예정. 글로벌 시장 확대 가능성으로 중간 중요도로 예상됨.
Related Recent Events
Chong Kun Dang Pharm Co (185750) · Earnings Release
Medium importance is estimated based on the potential for significant price movement following the announcement; Q2 2026 earnings release scheduled.
8/18/2026, 12:00:00 AM
HK inno N Corporation (195940) · Other
Announced on May 22, 2026, that cumulative outpatient prescriptions for K-CAB surpassed 1 trillion KRW; this milestone for the flagship drug is expected to strengthen market leadership.
5/22/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Daewoong Pharmaceutical announced a license-in agreement for a long-acting obesity treatment on 2026-05-21. This entry into the high-growth obesity market is estimated to cause a ≥10% price impact. scheduled
5/21/2026, 12:00:00 AM
HK inno N Corporation (195940) · Other
Announced a 97 billion KRW investment on May 21, 2026, to expand the Osong production facility; this capacity increase is expected to meet rising global demand.
5/21/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a 10-year supply contract with Organon worth 52.7 billion KRW to export three combination drugs for cardiovascular and respiratory diseases to Malaysia and the Philippines; low price impact estimated as the annual contract value is small relative to total revenue, scheduled.
5/21/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
Yuhan Corp announced a KRW 210.2 billion API supply agreement with Gilead Sciences on May 20, 2026, effective through December 31, 2027; high importance estimated as the contract value is approximately 11% of annual revenue, scheduled.
5/20/2026, 12:00:00 AM